Gallid herpesvirus 3 (ATCC® VR-2176)

Classification: Herpesviridae, Mardivirus  /  Product Format: frozen

Classification Herpesviridae, Mardivirus
Deposited As Marek's disease virus type 2
Agent Gallid herpesvirus 3
Strain 301B/1
Applications
Must be preserved in living cells to maintain viability (10% DMSO).
Must be preserved in living cells to maintain viability (10% DMSO).
Biosafety Level 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Product Format frozen
Storage Conditions -196C
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Comments
Must be preserved in living cells to maintain viability (10% DMSO). Vaccine strain.
Effect on Host
Cytopathic effects in tissue culture
Recommended Host
primary and secondary chicken embryo fibroblasts
Growth Conditions
Incubation: 3 days
Effect on Host
Cytopathic effects in tissue culture
Name of Depositor RL Witter
U.S. Patent
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
References

Witter RL. Serotype 2 Marek's disease vaccine. US Patent 4,895,718 dated Jan 23 1990